Oculis Holding AG
OCSHealthcareNASDAQBiotechnology · Last scanned Oct 26, 2026
Scan Results
Daily timeframePart of the healthcare sector, Oculis Holding AG (OCS) is listed under Biotechnology. The company carries a $486.5M market cap, placing it firmly in the small-cap category. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.
Market Cap
$486.5M
Beta
0.27
P/E (TTM)
—
P/E (Fwd)
-4.01
EPS (TTM)
$-1.74
EPS (Fwd)
$-1.97
ROE
-43.7%
ROA
-24.9%
Cash
$228.3M
Total Debt
$2.5M
Free CF
-$41.4M
52W Change
-63.3%
Annual Financials
Cash vs Debt
Where OCS stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, OCS finished 56.99% below its 150-day moving average ($17.02) and 62.37% below its 200-day moving average ($19.45). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is OCS overbought or oversold?
At the October 20, 2026 close, OCS's RSI(14) was 23.3, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Oculis Holding AG holds $228.3M in cash against $2.5M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$41.4M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -43.7%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
The relatively low beta of 0.27 suggests OCS is a less volatile holding compared to the broader index. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Oculis Holding AG and its sector.